HRP20211077T1 - Farmaceutski pripravci koji sadrže natrij-nitrit - Google Patents
Farmaceutski pripravci koji sadrže natrij-nitrit Download PDFInfo
- Publication number
- HRP20211077T1 HRP20211077T1 HRP20211077TT HRP20211077T HRP20211077T1 HR P20211077 T1 HRP20211077 T1 HR P20211077T1 HR P20211077T T HRP20211077T T HR P20211077TT HR P20211077 T HRP20211077 T HR P20211077T HR P20211077 T1 HRP20211077 T1 HR P20211077T1
- Authority
- HR
- Croatia
- Prior art keywords
- sodium nitrite
- ppm
- disease
- tissue
- ischemia
- Prior art date
Links
- LPXPTNMVRIOKMN-UHFFFAOYSA-M sodium nitrite Chemical compound [Na+].[O-]N=O LPXPTNMVRIOKMN-UHFFFAOYSA-M 0.000 title claims 26
- 235000010288 sodium nitrite Nutrition 0.000 title claims 13
- 239000008194 pharmaceutical composition Substances 0.000 title 1
- 206010002383 Angina Pectoris Diseases 0.000 claims 4
- 230000017531 blood circulation Effects 0.000 claims 4
- 210000000748 cardiovascular system Anatomy 0.000 claims 4
- 201000010099 disease Diseases 0.000 claims 4
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 4
- 238000000034 method Methods 0.000 claims 4
- 208000031225 myocardial ischemia Diseases 0.000 claims 4
- 208000024172 Cardiovascular disease Diseases 0.000 claims 2
- 208000032064 Chronic Limb-Threatening Ischemia Diseases 0.000 claims 2
- 206010022562 Intermittent claudication Diseases 0.000 claims 2
- XEEYBQQBJWHFJM-UHFFFAOYSA-N Iron Chemical compound [Fe] XEEYBQQBJWHFJM-UHFFFAOYSA-N 0.000 claims 2
- 206010034576 Peripheral ischaemia Diseases 0.000 claims 2
- 206010063837 Reperfusion injury Diseases 0.000 claims 2
- CDBYLPFSWZWCQE-UHFFFAOYSA-L Sodium Carbonate Chemical compound [Na+].[Na+].[O-]C([O-])=O CDBYLPFSWZWCQE-UHFFFAOYSA-L 0.000 claims 2
- 208000007536 Thrombosis Diseases 0.000 claims 2
- 238000002399 angioplasty Methods 0.000 claims 2
- 230000002612 cardiopulmonary effect Effects 0.000 claims 2
- 210000003169 central nervous system Anatomy 0.000 claims 2
- 208000024980 claudication Diseases 0.000 claims 2
- 208000029078 coronary artery disease Diseases 0.000 claims 2
- 239000003937 drug carrier Substances 0.000 claims 2
- 208000028867 ischemia Diseases 0.000 claims 2
- 208000012947 ischemia reperfusion injury Diseases 0.000 claims 2
- 230000000302 ischemic effect Effects 0.000 claims 2
- 208000030613 peripheral artery disease Diseases 0.000 claims 2
- 239000000546 pharmaceutical excipient Substances 0.000 claims 2
- 239000000825 pharmaceutical preparation Substances 0.000 claims 2
- VWDWKYIASSYTQR-UHFFFAOYSA-N sodium nitrate Chemical compound [Na+].[O-][N+]([O-])=O VWDWKYIASSYTQR-UHFFFAOYSA-N 0.000 claims 2
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 claims 1
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 claims 1
- VEXZGXHMUGYJMC-UHFFFAOYSA-M Chloride anion Chemical compound [Cl-] VEXZGXHMUGYJMC-UHFFFAOYSA-M 0.000 claims 1
- 239000001692 EU approved anti-caking agent Substances 0.000 claims 1
- ZLMJMSJWJFRBEC-UHFFFAOYSA-N Potassium Chemical compound [K] ZLMJMSJWJFRBEC-UHFFFAOYSA-N 0.000 claims 1
- 240000004808 Saccharomyces cerevisiae Species 0.000 claims 1
- BUGBHKTXTAQXES-UHFFFAOYSA-N Selenium Chemical compound [Se] BUGBHKTXTAQXES-UHFFFAOYSA-N 0.000 claims 1
- QAOWNCQODCNURD-UHFFFAOYSA-L Sulfate Chemical compound [O-]S([O-])(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-L 0.000 claims 1
- 229910052782 aluminium Inorganic materials 0.000 claims 1
- XAGFODPZIPBFFR-UHFFFAOYSA-N aluminium Chemical compound [Al] XAGFODPZIPBFFR-UHFFFAOYSA-N 0.000 claims 1
- 229910052785 arsenic Inorganic materials 0.000 claims 1
- RQNWIZPPADIBDY-UHFFFAOYSA-N arsenic atom Chemical compound [As] RQNWIZPPADIBDY-UHFFFAOYSA-N 0.000 claims 1
- 239000011575 calcium Substances 0.000 claims 1
- 229910052791 calcium Inorganic materials 0.000 claims 1
- 229910052799 carbon Inorganic materials 0.000 claims 1
- 238000004737 colorimetric analysis Methods 0.000 claims 1
- 230000003247 decreasing effect Effects 0.000 claims 1
- 238000001035 drying Methods 0.000 claims 1
- 239000002158 endotoxin Substances 0.000 claims 1
- 229910001385 heavy metal Inorganic materials 0.000 claims 1
- 239000012535 impurity Substances 0.000 claims 1
- 229910052742 iron Inorganic materials 0.000 claims 1
- QSHDDOUJBYECFT-UHFFFAOYSA-N mercury Chemical compound [Hg] QSHDDOUJBYECFT-UHFFFAOYSA-N 0.000 claims 1
- 229910052753 mercury Inorganic materials 0.000 claims 1
- 230000002906 microbiologic effect Effects 0.000 claims 1
- 229910052700 potassium Inorganic materials 0.000 claims 1
- 239000011591 potassium Substances 0.000 claims 1
- 229910052711 selenium Inorganic materials 0.000 claims 1
- 239000011669 selenium Substances 0.000 claims 1
- 229910000029 sodium carbonate Inorganic materials 0.000 claims 1
- 235000010344 sodium nitrate Nutrition 0.000 claims 1
- 239000004317 sodium nitrate Substances 0.000 claims 1
- 239000000126 substance Substances 0.000 claims 1
- 208000011580 syndromic disease Diseases 0.000 claims 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K33/00—Medicinal preparations containing inorganic active ingredients
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/16—Amides, e.g. hydroxamic acids
- A61K31/17—Amides, e.g. hydroxamic acids having the group >N—C(O)—N< or >N—C(S)—N<, e.g. urea, thiourea, carmustine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4418—Non condensed pyridines; Hydrogenated derivatives thereof having a carbocyclic group directly attached to the heterocyclic ring, e.g. cyproheptadine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/4709—Non-condensed quinolines and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/08—Solutions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- C—CHEMISTRY; METALLURGY
- C01—INORGANIC CHEMISTRY
- C01B—NON-METALLIC ELEMENTS; COMPOUNDS THEREOF; METALLOIDS OR COMPOUNDS THEREOF NOT COVERED BY SUBCLASS C01C
- C01B21/00—Nitrogen; Compounds thereof
- C01B21/20—Nitrogen oxides; Oxyacids of nitrogen; Salts thereof
- C01B21/50—Nitrous acid; Salts thereof
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
- Y10T—TECHNICAL SUBJECTS COVERED BY FORMER US CLASSIFICATION
- Y10T436/00—Chemistry: analytical and immunological testing
- Y10T436/20—Oxygen containing
- Y10T436/204998—Inorganic carbon compounds
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Epidemiology (AREA)
- Organic Chemistry (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Inorganic Chemistry (AREA)
- Dermatology (AREA)
- Cardiology (AREA)
- Pulmonology (AREA)
- Heart & Thoracic Surgery (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Claims (3)
1. Natrijev nitrit koji sadrži najviše 0.02 mas.% natrijevog karbonata i najviše 10 ppm sredstva protiv zgrušavanja,
pri čemu natrijev nitrit ima gubitak pri sušenju ne veći od 0.25 mas.%;
pri čemu sadržaj vode u natrijevom nitritu nije veći od 0.5 mas.%;
pri čemu natrijev nitrit ne sadrži više od 0.4 mas.% natrij nitrata, ne više od 0.005 mas.% netopivih tvari, ne više od 0.005 mas.% klorida, ne više od 0.01 mas.% sulfata, ne više od 0.001 mas.% željeza, ne više od 0.01 mas.% kalcija, ne više od 0.005 mas.% kalija, ne više od 0.05 ppm žive, ne više od 2 ppm aluminija, ne više od 3 ppm arsena i ne više od 0.003% masenog udjela selena;
pri čemu natrijev nitrit ne sadrži više od 10 ppm, ne više od 100 ppm, ne više od 500 ppm, ne više od 1000 ppm ili ne više od 5000 ppm organskih hlapivih nečistoća;
pri čemu ukupan sadržaj hlapljivog organskog ugljika u natrijevom nitritu nije veći od 2.5 ppm ili ne veći od 10 ppm; pri čemu natrijev nitrit ima ukupni aerobni broj mikrobiološkog opterećenja ne veći od 100 CFU/g, ukupni broj kvasca i plijesni ne veći od 20 CFU/g, ne sadrži više od 0.25 EU/mg bakterijskih endotoksina;
pri čemu natrijev nitrit sadrži ne manje od 97 mas.% i ne više od 101 mas.% natrij nitrita, mjereno USP kolormetrijskim testom; i
pri čemu sadržaj teških metala u natrijevom nitritu nije veći od 10 ppm,
za uporabu u metodi liječenja, prevencije ili smanjenja rizika od bolesti ili stanja povezanih s kardiovaskularnim sustavom, pri čemu je bolest ili stanje povezano s kardiovaskularnim sustavom angina, klaudikacija, bolest perifernih arterija, kritična ishemija udova, ishemija tkiva reperfuzijska ozljeda, intravaskularna tromboza, ishemijski događaj središnjeg živčanog sustava ili kardiovaskularna bolest;
ili za upotrebu u metodi za povećanje protoka krvi u tkivu, pri čemu se protok krvi u navedeno tkivo smanjuje izravno ili neizravno kardiopulmonalnom premosnicom, koronarnom bolešću, sindromom srčane ishemije, anginom, angioplastikom, ishemijom miokarda ili ishemijom tkiva.
2. Farmaceutski pripravak, naznačen time što sadrži natrijev nitrit prema zahtjevu 1 i jedan ili više farmaceutski prihvatljivih nosača ili pomoćnih tvari za uporabu u metodi liječenja, sprečavanja ili smanjenja rizika od bolesti ili stanja povezanih s kardiovaskularnim sustavom, pri čemu bolest ili stanje povezana s kardiovaskularnim sustavom je angina, klaudikacija, bolest perifernih arterija, kritična ishemija udova, ishemija tkiva-reperfuzijska ozljeda, intravaskularna tromboza, ishemijski događaj središnjeg živčanog sustava ili kardiovaskularna bolest.
3. Farmaceutski pripravak, naznačen time što sadrži natrijev nitrit prema zahtjevu 1 i jedan ili više farmaceutski prihvatljivih nosača ili pomoćnih tvari za uporabu u metodi za povećanje protoka krvi u tkivu, pri čemu se protok krvi u navedeno tkivo smanjuje izravno ili neizravno kardiopulmonalnom premosnicom, koronarnom bolešću , sindromom srčane ishemije, anginom, angioplastikom, ishemijom miokarda ili ishemijom tkiva.
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US15182009P | 2009-02-11 | 2009-02-11 | |
| US22402109P | 2009-07-08 | 2009-07-08 | |
| EP19177863.8A EP3569237B1 (en) | 2009-02-11 | 2010-02-11 | Sodium nitrite-containing pharmaceutical compositions |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| HRP20211077T1 true HRP20211077T1 (hr) | 2021-10-01 |
Family
ID=42540617
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| HRP20191516 HRP20191516T1 (hr) | 2009-02-11 | 2019-08-22 | Farmaceutski pripravci koji sadrže natrij-nitrit |
| HRP20211077TT HRP20211077T1 (hr) | 2009-02-11 | 2021-07-06 | Farmaceutski pripravci koji sadrže natrij-nitrit |
Family Applications Before (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| HRP20191516 HRP20191516T1 (hr) | 2009-02-11 | 2019-08-22 | Farmaceutski pripravci koji sadrže natrij-nitrit |
Country Status (15)
| Country | Link |
|---|---|
| US (13) | US8568793B2 (hr) |
| EP (3) | EP3569237B1 (hr) |
| JP (2) | JP5789519B2 (hr) |
| AU (1) | AU2010213743C1 (hr) |
| CA (1) | CA2752129C (hr) |
| CY (2) | CY1121939T1 (hr) |
| DK (2) | DK2395834T3 (hr) |
| ES (2) | ES2880500T3 (hr) |
| HR (2) | HRP20191516T1 (hr) |
| HU (2) | HUE044781T2 (hr) |
| LT (2) | LT3569237T (hr) |
| PL (2) | PL3569237T3 (hr) |
| PT (2) | PT3569237T (hr) |
| SI (2) | SI3569237T1 (hr) |
| WO (1) | WO2010093746A1 (hr) |
Families Citing this family (30)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ES2294543T3 (es) | 2003-07-09 | 2008-04-01 | The Government Of The United States Of America, As Represented By The Secretary, Department Of Heal | Uso de sales de nitrilo para el tratamiento de afecciones cardiovasculares. |
| AU2008322437B2 (en) | 2007-11-15 | 2013-11-07 | Louisiana State University | Use of nitrite salts in chronic ischemia |
| CA2710349A1 (en) * | 2007-12-27 | 2009-07-09 | Aires Pharmaceuticals, Inc. | Aerosolized nitrite and nitric oxide -donating compounds and uses thereof |
| US8568793B2 (en) | 2009-02-11 | 2013-10-29 | Hope Medical Enterprises, Inc. | Sodium nitrite-containing pharmaceutical compositions |
| WO2010147742A2 (en) | 2009-06-18 | 2010-12-23 | Theravasc Inc. | Use of nitrite salts in treating tissue damage |
| CA2767168C (en) | 2009-07-08 | 2019-04-09 | Hope Medical Enterprises, Inc. D.B.A. Hope Pharmaceuticals | Sodium thiosulfate-containing pharmaceutical compositions |
| EP2488035B1 (en) * | 2009-10-14 | 2017-04-26 | Theravasc Inc. | Pharmaceutical formulations of nitrite and uses thereof |
| US20130209584A1 (en) * | 2009-10-14 | 2013-08-15 | Theravasc Inc. | Pharmaceutical formulations of nitrite and uses thereof |
| US20140127329A1 (en) * | 2011-03-31 | 2014-05-08 | Board Of Supervisors Of Louisiana State University And Agricultural And Mechanical College | Use of nitrites for the treatment of cerebral amyloid angiopathy, age associated dementia, and cognitive decline |
| CN102565230B (zh) * | 2012-01-09 | 2013-12-11 | 山东大学 | 一种聚异丁烯中游离氯离子的检测方法 |
| AU2014218916A1 (en) | 2013-02-20 | 2015-09-03 | Theravasc Inc. | Pharmaceutical formulations of nitrite and uses thereof |
| WO2015168322A1 (en) * | 2014-04-29 | 2015-11-05 | Douglas Seals | Methods for treatment of motor and cognitive functions using sodium nitrite |
| GB201602959D0 (en) | 2016-02-19 | 2016-04-06 | Isis Innovation | Use of cerebral nitric oxide donors in the assessment of the extent of brain dyfunction following injury |
| CN106268664A (zh) * | 2016-08-28 | 2017-01-04 | 铜仁市万山区盛和矿业有限责任公司 | 一种含汞废水的处理剂及其制备方法 |
| EP3592342A4 (en) | 2017-03-08 | 2020-12-23 | Hope Medical Enterprise, Inc. D.b.a. Hope Pharmaceuticals | INTRADIALYTICAL USE OF SODIUM NITRITE |
| NZ756704A (en) | 2017-03-08 | 2022-07-01 | Hope Medical Entpr Inc Dba Hope Pharmaceuticals | Intradialytic use of sodium thiosulfate |
| WO2019157295A1 (en) * | 2018-02-09 | 2019-08-15 | The Trustees Of Columbia University In The City Of New York | Treating infections using inhibitor of cbb3-type oxidases |
| EP3801378A4 (en) | 2018-05-24 | 2022-02-23 | Celanese EVA Performance Polymers LLC | IMPLANTABLE DEVICE FOR THE DELAYED RELEASE OF A MACROMOLECULAR DRUG COMPOUND |
| CN111971026A (zh) | 2018-05-24 | 2020-11-20 | 塞拉尼斯伊娃高性能聚合物公司 | 用于持续释放大分子药物化合物的可植入器件 |
| GB2599818B (en) | 2019-06-04 | 2024-01-31 | Thirty Respiratory Ltd | Methods and compositions for generating nitric oxide and uses thereof to deliver nitric oxide via the respiratory tract |
| CA3142101A1 (en) | 2019-06-04 | 2020-12-10 | Thirty Holdings Limited | Methods and compositions for generating nitric oxide and uses thereof |
| JP2023526583A (ja) | 2020-04-23 | 2023-06-22 | サーティー レスピラトリー リミテッド | 結核を治療及び抑制するための方法及び組成物 |
| JP2023526584A (ja) | 2020-04-23 | 2023-06-22 | サーティー レスピラトリー リミテッド | Ｓａｒｓ－ｃｏｖ及びｓａｒｓ－ｃｏｖ－２の治療に使用するための一酸化窒素または一酸化窒素放出組成物 |
| WO2022049555A1 (en) * | 2020-09-07 | 2022-03-10 | Deepak Nitrite Limited | A free-flowing food grade sodium nitrite and production method thereof |
| GB202101543D0 (en) | 2021-02-04 | 2021-03-24 | Thirty Respiratory Ltd | Vaping e-liquid composition and the use thereof |
| WO2023118839A1 (en) | 2021-12-22 | 2023-06-29 | Thirty Holdings Limited | Powder composition |
| WO2023118841A2 (en) | 2021-12-22 | 2023-06-29 | Thirty Holdings Limited | Powder composition |
| WO2023152656A2 (en) * | 2022-02-08 | 2023-08-17 | Visolis Technologies, Inc. | Novel highly sustainable compositions for modulation of gene expression in human skin, and methods of production thereof |
| GB202215521D0 (en) | 2022-10-20 | 2022-12-07 | Thirty Holdings Ltd | Wound dressings |
| GB202215758D0 (en) | 2022-10-25 | 2022-12-07 | Thirty Holdings Ltd | Implantable medical devices |
Family Cites Families (95)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US2032699A (en) * | 1932-07-23 | 1936-03-03 | Solvay Process Co | Process for the production of sodium nitrite |
| NL203871A (hr) | 1955-02-09 | 1900-01-01 | ||
| US2933377A (en) * | 1956-08-01 | 1960-04-19 | Du Pont | Process for making non-caking and free-flowing sodium nitrite |
| US3536809A (en) | 1969-02-17 | 1970-10-27 | Alza Corp | Medication method |
| US3598123A (en) | 1969-04-01 | 1971-08-10 | Alza Corp | Bandage for administering drugs |
| US3845770A (en) | 1972-06-05 | 1974-11-05 | Alza Corp | Osmatic dispensing device for releasing beneficial agent |
| US3916899A (en) | 1973-04-25 | 1975-11-04 | Alza Corp | Osmotic dispensing device with maximum and minimum sizes for the passageway |
| US3958941A (en) * | 1975-02-06 | 1976-05-25 | Sybron Corporation | Apparatus for measuring content of organic carbon |
| US3965247A (en) * | 1975-06-20 | 1976-06-22 | Allied Chemical Corporation | Recovery of sodium nitrite from by-product process liquors containing sodium chloride |
| US4008719A (en) | 1976-02-02 | 1977-02-22 | Alza Corporation | Osmotic system having laminar arrangement for programming delivery of active agent |
| US4543190A (en) | 1980-05-08 | 1985-09-24 | Modar, Inc. | Processing methods for the oxidation of organics in supercritical water |
| US4292311A (en) * | 1980-12-23 | 1981-09-29 | Sarnoff Stanley J | Cyanide antidote |
| US4410545A (en) | 1981-02-13 | 1983-10-18 | Syntex (U.S.A.) Inc. | Carbonate diester solutions of PGE-type compounds |
| US4328245A (en) | 1981-02-13 | 1982-05-04 | Syntex (U.S.A.) Inc. | Carbonate diester solutions of PGE-type compounds |
| US4409239A (en) | 1982-01-21 | 1983-10-11 | Syntex (U.S.A.) Inc. | Propylene glycol diester solutions of PGE-type compounds |
| KR890002631B1 (ko) | 1984-10-04 | 1989-07-21 | 몬산토 캄파니 | 생물학적으로 활성인 소마토트로핀을 지속적으로 유리하는 조성물 |
| IE58110B1 (en) | 1984-10-30 | 1993-07-14 | Elan Corp Plc | Controlled release powder and process for its preparation |
| US5033252A (en) | 1987-12-23 | 1991-07-23 | Entravision, Inc. | Method of packaging and sterilizing a pharmaceutical product |
| US5052558A (en) | 1987-12-23 | 1991-10-01 | Entravision, Inc. | Packaged pharmaceutical product |
| US5073543A (en) | 1988-07-21 | 1991-12-17 | G. D. Searle & Co. | Controlled release formulations of trophic factors in ganglioside-lipsome vehicle |
| US5612059A (en) | 1988-08-30 | 1997-03-18 | Pfizer Inc. | Use of asymmetric membranes in delivery devices |
| IT1229203B (it) | 1989-03-22 | 1991-07-25 | Bioresearch Spa | Impiego di acido 5 metiltetraidrofolico, di acido 5 formiltetraidrofolico e dei loro sali farmaceuticamente accettabili per la preparazione di composizioni farmaceutiche in forma a rilascio controllato attive nella terapia dei disturbi mentali organici e composizioni farmaceutiche relative. |
| PH30995A (en) | 1989-07-07 | 1997-12-23 | Novartis Inc | Sustained release formulations of water soluble peptides. |
| US5120548A (en) | 1989-11-07 | 1992-06-09 | Merck & Co., Inc. | Swelling modulated polymeric drug delivery device |
| US5585112A (en) | 1989-12-22 | 1996-12-17 | Imarx Pharmaceutical Corp. | Method of preparing gas and gaseous precursor-filled microspheres |
| IT1246382B (it) | 1990-04-17 | 1994-11-18 | Eurand Int | Metodo per la cessione mirata e controllata di farmaci nell'intestino e particolarmente nel colon |
| US5733566A (en) | 1990-05-15 | 1998-03-31 | Alkermes Controlled Therapeutics Inc. Ii | Controlled release of antiparasitic agents in animals |
| US5156850A (en) * | 1990-08-31 | 1992-10-20 | Alza Corporation | Dosage form for time-varying patterns of drug delivery |
| US5543390A (en) | 1990-11-01 | 1996-08-06 | State Of Oregon, Acting By And Through The Oregon State Board Of Higher Education, Acting For And On Behalf Of The Oregon Health Sciences University | Covalent microparticle-drug conjugates for biological targeting |
| USH1126H (en) * | 1991-11-12 | 1993-01-05 | The United States Of America As Represented By The Secretary Of The Navy | Treatment of sodium nitrite-containing boiler wastewater |
| US5580578A (en) | 1992-01-27 | 1996-12-03 | Euro-Celtique, S.A. | Controlled release formulations coated with aqueous dispersions of acrylic polymers |
| US5323907A (en) | 1992-06-23 | 1994-06-28 | Multi-Comp, Inc. | Child resistant package assembly for dispensing pharmaceutical medications |
| TW333456B (en) | 1992-12-07 | 1998-06-11 | Takeda Pharm Ind Co Ltd | A pharmaceutical composition of sustained-release preparation the invention relates to a pharmaceutical composition of sustained-release preparation which comprises a physiologically active peptide. |
| US5591767A (en) | 1993-01-25 | 1997-01-07 | Pharmetrix Corporation | Liquid reservoir transdermal patch for the administration of ketorolac |
| US6274552B1 (en) | 1993-03-18 | 2001-08-14 | Cytimmune Sciences, Inc. | Composition and method for delivery of biologically-active factors |
| US5405533A (en) | 1993-04-07 | 1995-04-11 | General Atomics | Heat transfer via dense gas in a fluid circulation system |
| US5523092A (en) | 1993-04-14 | 1996-06-04 | Emory University | Device for local drug delivery and methods for using the same |
| US5985307A (en) | 1993-04-14 | 1999-11-16 | Emory University | Device and method for non-occlusive localized drug delivery |
| US6087324A (en) | 1993-06-24 | 2000-07-11 | Takeda Chemical Industries, Ltd. | Sustained-release preparation |
| US6004534A (en) | 1993-07-23 | 1999-12-21 | Massachusetts Institute Of Technology | Targeted polymerized liposomes for improved drug delivery |
| US5387398A (en) | 1993-12-03 | 1995-02-07 | Aerojet General Corporation | Supercritical water oxidation reactor with wall conduits for boundary flow control |
| US6709681B2 (en) | 1995-02-17 | 2004-03-23 | Aberdeen University | Acidified nitrite as an antimicrobial agent |
| US6056883A (en) | 1994-06-07 | 2000-05-02 | Abitibi Consolidated Inc. | Method and apparatus to remove inorganic scale from a supercritical water oxidation reactor |
| US5501799A (en) | 1994-06-07 | 1996-03-26 | Abitibi-Price, Inc. | Method to remove inorganic scale from a supercritical water oxidation reactor |
| IT1270594B (it) | 1994-07-07 | 1997-05-07 | Recordati Chem Pharm | Composizione farmaceutica a rilascio controllato di moguisteina in sospensione liquida |
| US5759542A (en) | 1994-08-05 | 1998-06-02 | New England Deaconess Hospital Corporation | Compositions and methods for the delivery of drugs by platelets for the treatment of cardiovascular and other diseases |
| US5660854A (en) | 1994-11-28 | 1997-08-26 | Haynes; Duncan H | Drug releasing surgical implant or dressing material |
| US6316652B1 (en) | 1995-06-06 | 2001-11-13 | Kosta Steliou | Drug mitochondrial targeting agents |
| US5798119A (en) | 1995-06-13 | 1998-08-25 | S. C. Johnson & Son, Inc. | Osmotic-delivery devices having vapor-permeable coatings |
| EP0835101B1 (en) | 1995-06-27 | 2004-06-09 | Takeda Chemical Industries, Ltd. | Method of producing sustained-release preparation |
| TW448055B (en) | 1995-09-04 | 2001-08-01 | Takeda Chemical Industries Ltd | Method of production of sustained-release preparation |
| JP2909418B2 (ja) | 1995-09-18 | 1999-06-23 | 株式会社資生堂 | 薬物の遅延放出型マイクロスフイア |
| US6039975A (en) | 1995-10-17 | 2000-03-21 | Hoffman-La Roche Inc. | Colon targeted delivery system |
| US5980945A (en) | 1996-01-16 | 1999-11-09 | Societe De Conseils De Recherches Et D'applications Scientifique S.A. | Sustained release drug formulations |
| US5804066A (en) | 1996-02-08 | 1998-09-08 | Aerojet-General Corporation | Injector for SCWO reactor |
| TW345603B (en) | 1996-05-29 | 1998-11-21 | Gmundner Fertigteile Gmbh | A noise control device for tracks |
| US6264970B1 (en) | 1996-06-26 | 2001-07-24 | Takeda Chemical Industries, Ltd. | Sustained-release preparation |
| US6419961B1 (en) | 1996-08-29 | 2002-07-16 | Takeda Chemical Industries, Ltd. | Sustained release microcapsules of a bioactive substance and a biodegradable polymer |
| WO1998014179A1 (en) | 1996-10-01 | 1998-04-09 | Cima Labs Inc. | Taste-masked microcapsule compositions and methods of manufacture |
| CA2217134A1 (en) | 1996-10-09 | 1998-04-09 | Sumitomo Pharmaceuticals Co., Ltd. | Sustained release formulation |
| DE69730093T2 (de) | 1996-10-31 | 2006-07-20 | Takeda Pharmaceutical Co. Ltd. | Zubereitung mit verzögerter Freisetzung |
| US6131570A (en) | 1998-06-30 | 2000-10-17 | Aradigm Corporation | Temperature controlling device for aerosol drug delivery |
| US6197350B1 (en) | 1996-12-20 | 2001-03-06 | Takeda Chemical Industries, Ltd. | Method of producing a sustained-release preparation |
| US5891474A (en) | 1997-01-29 | 1999-04-06 | Poli Industria Chimica, S.P.A. | Time-specific controlled release dosage formulations and method of preparing same |
| US6120751A (en) | 1997-03-21 | 2000-09-19 | Imarx Pharmaceutical Corp. | Charged lipids and uses for the same |
| US6060082A (en) | 1997-04-18 | 2000-05-09 | Massachusetts Institute Of Technology | Polymerized liposomes targeted to M cells and useful for oral or mucosal drug delivery |
| US6054057A (en) | 1997-09-26 | 2000-04-25 | General Atomics | Downflow hydrothermal treatment |
| US6350458B1 (en) | 1998-02-10 | 2002-02-26 | Generex Pharmaceuticals Incorporated | Mixed micellar drug deliver system and method of preparation |
| US6613358B2 (en) | 1998-03-18 | 2003-09-02 | Theodore W. Randolph | Sustained-release composition including amorphous polymer |
| US6048736A (en) | 1998-04-29 | 2000-04-11 | Kosak; Kenneth M. | Cyclodextrin polymers for carrying and releasing drugs |
| KR19990085365A (ko) | 1998-05-16 | 1999-12-06 | 허영섭 | 지속적으로 약물 조절방출이 가능한 생분해성 고분자 미립구 및그 제조방법 |
| US6248363B1 (en) | 1999-11-23 | 2001-06-19 | Lipocine, Inc. | Solid carriers for improved delivery of active ingredients in pharmaceutical compositions |
| US6251354B1 (en) * | 1999-04-02 | 2001-06-26 | General Electric Co. | Process for recovering sodium nitrite |
| US6271359B1 (en) | 1999-04-14 | 2001-08-07 | Musc Foundation For Research Development | Tissue-specific and pathogen-specific toxic agents and ribozymes |
| US6238568B1 (en) | 1999-05-06 | 2001-05-29 | General Atomics | Hydrothermal processing with phosphate additive |
| JP2004507502A (ja) | 2000-08-30 | 2004-03-11 | ファイザー・プロダクツ・インク | 成長ホルモン分泌促進物質のための徐放性製剤 |
| GB0022084D0 (en) * | 2000-09-08 | 2000-10-25 | Univ Aberdeen | Treatment of multiply antibiotic-resistant organisms |
| US6576185B2 (en) | 2000-12-28 | 2003-06-10 | General Atomics | System and method for hydrothermal reactions-three layer liner |
| US6709602B2 (en) | 2001-04-23 | 2004-03-23 | General Atomics | Process for hydrothermal treatment of materials |
| US6519926B2 (en) | 2001-05-01 | 2003-02-18 | General Atomics | Hydrothermal conversion and separation |
| US6773581B2 (en) | 2001-10-18 | 2004-08-10 | General Atomics | System and method for solids transport in hydrothermal processes |
| GB0125222D0 (en) * | 2001-10-19 | 2001-12-12 | Barts & London Nhs Trust | Composition for the treatment of microbial infections |
| US6855306B2 (en) * | 2002-09-26 | 2005-02-15 | General Chemical Performance Products Llc | Process for the recovery of sodium nitrite |
| AU2003304398A1 (en) * | 2002-10-16 | 2005-02-25 | Board Of Regents, The University Of Texas System | Methods and compositions for increasing the efficacy of biologically-active ingredients |
| ES2294543T3 (es) * | 2003-07-09 | 2008-04-01 | The Government Of The United States Of America, As Represented By The Secretary, Department Of Heal | Uso de sales de nitrilo para el tratamiento de afecciones cardiovasculares. |
| US8486374B2 (en) * | 2003-08-04 | 2013-07-16 | Foamix Ltd. | Hydrophilic, non-aqueous pharmaceutical carriers and compositions and uses |
| US20080069779A1 (en) * | 2003-08-04 | 2008-03-20 | Foamix Ltd. | Foamable vehicle and vitamin and flavonoid pharmaceutical compositions thereof |
| CA2549544A1 (en) * | 2003-12-15 | 2005-06-23 | Nitricare Hb | Device and method for administering therapeutic agents |
| US20050260112A1 (en) * | 2004-05-19 | 2005-11-24 | Hensman Carl E | Removal of elemental mercury from gas by modifying wet scrubber systems with an organic compound |
| US7362274B1 (en) * | 2004-07-09 | 2008-04-22 | Huan-Cheng Lien | Coupled feed-in butterfly shaped left/right hand circularly polarized microstrip antenna |
| US8557300B2 (en) * | 2005-05-19 | 2013-10-15 | University Of Cincinnati | Methods for treating bacterial respiratory tract infections in an individual using acidified nitrite |
| AU2008322437B2 (en) * | 2007-11-15 | 2013-11-07 | Louisiana State University | Use of nitrite salts in chronic ischemia |
| CA2710349A1 (en) * | 2007-12-27 | 2009-07-09 | Aires Pharmaceuticals, Inc. | Aerosolized nitrite and nitric oxide -donating compounds and uses thereof |
| US8568793B2 (en) * | 2009-02-11 | 2013-10-29 | Hope Medical Enterprises, Inc. | Sodium nitrite-containing pharmaceutical compositions |
| CA2767168C (en) | 2009-07-08 | 2019-04-09 | Hope Medical Enterprises, Inc. D.B.A. Hope Pharmaceuticals | Sodium thiosulfate-containing pharmaceutical compositions |
-
2010
- 2010-02-10 US US12/703,448 patent/US8568793B2/en active Active
- 2010-02-11 PL PL19177863T patent/PL3569237T3/pl unknown
- 2010-02-11 LT LTEP19177863.8T patent/LT3569237T/lt unknown
- 2010-02-11 SI SI201032075T patent/SI3569237T1/sl unknown
- 2010-02-11 EP EP19177863.8A patent/EP3569237B1/en active Active
- 2010-02-11 ES ES19177863T patent/ES2880500T3/es active Active
- 2010-02-11 HU HUE10741692 patent/HUE044781T2/hu unknown
- 2010-02-11 EP EP21161011.8A patent/EP3862007A1/en active Pending
- 2010-02-11 JP JP2011550214A patent/JP5789519B2/ja active Active
- 2010-02-11 WO PCT/US2010/023824 patent/WO2010093746A1/en active Application Filing
- 2010-02-11 ES ES10741692T patent/ES2743303T3/es active Active
- 2010-02-11 PL PL10741692T patent/PL2395834T3/pl unknown
- 2010-02-11 SI SI201031926T patent/SI2395834T1/sl unknown
- 2010-02-11 LT LT10741692T patent/LT2395834T/lt unknown
- 2010-02-11 CA CA2752129A patent/CA2752129C/en active Active
- 2010-02-11 PT PT191778638T patent/PT3569237T/pt unknown
- 2010-02-11 AU AU2010213743A patent/AU2010213743C1/en active Active
- 2010-02-11 PT PT10741692T patent/PT2395834T/pt unknown
- 2010-02-11 DK DK10741692.7T patent/DK2395834T3/da active
- 2010-02-11 DK DK19177863.8T patent/DK3569237T3/da active
- 2010-02-11 EP EP10741692.7A patent/EP2395834B1/en active Active
- 2010-02-11 HU HUE19177863A patent/HUE055250T2/hu unknown
-
2013
- 2013-10-01 US US14/042,783 patent/US8920852B2/en active Active
-
2014
- 2014-11-19 US US14/547,255 patent/US9597354B2/en active Active
- 2014-11-19 US US14/547,245 patent/US9283249B2/en active Active
-
2015
- 2015-06-22 JP JP2015124374A patent/JP6059297B2/ja active Active
-
2016
- 2016-02-08 US US15/017,772 patent/US9504709B2/en active Active
- 2016-08-29 US US15/249,746 patent/US9687505B2/en active Active
- 2016-08-30 US US15/251,015 patent/US9687506B2/en active Active
-
2017
- 2017-05-19 US US15/599,617 patent/US10251910B2/en active Active
-
2018
- 2018-05-08 US US15/973,659 patent/US10456417B2/en active Active
-
2019
- 2019-08-22 HR HRP20191516 patent/HRP20191516T1/hr unknown
- 2019-08-27 CY CY20191100910T patent/CY1121939T1/el unknown
- 2019-09-23 US US16/578,671 patent/US10874691B2/en active Active
-
2020
- 2020-04-08 US US16/842,939 patent/US10898513B2/en active Active
- 2020-12-18 US US17/126,329 patent/US11583550B2/en active Active
-
2021
- 2021-06-28 CY CY20211100571T patent/CY1124426T1/el unknown
- 2021-07-06 HR HRP20211077TT patent/HRP20211077T1/hr unknown
-
2023
- 2023-01-18 US US18/098,361 patent/US20230256006A1/en active Pending
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| HRP20211077T1 (hr) | Farmaceutski pripravci koji sadrže natrij-nitrit | |
| HRP20210239T1 (hr) | Tetrahidrobiopterin za liječenje stanja povezanih s povišenim razinama fenilalanina | |
| HRP20220902T3 (hr) | Pripravci i njihova upotreba u liječenju multiple skleroze | |
| JP2010520246A5 (hr) | ||
| TW200727903A (en) | Stable pharmaceutical compositions of 5, 10 methylenetetrahydrofolate | |
| JP2007504168A5 (hr) | ||
| Rubenowitz et al. | Magnesium in drinking water and body magnesium status measured using an oral loading test | |
| Sahiti et al. | Metal accumulation and effect of vitamin C and E in accumulated heavy metals in different tissues in common carp (Cyprinus carpio) treated with heavy metals | |
| JP2006511538A5 (hr) | ||
| Guilhot et al. | Significant Higher Rates of Undetectable Molecular Residual Disease and Molecular Responses with Pegylated Form of Interferon a2a in Combination with Imatinib (IM) for the Treatment of Newly Diagnosed Chronic Phase (CP) Chronic Myeloid Leukaemia (CML) Patients (pts): Confirmatory Results at 18 Months of Part 1 of the Spirit Phase III Randomized Trial of the French CML Group (FI LMC). | |
| ATE521602T1 (de) | Benzothiophen-2-carbonylguanidinderivate, deren herstellung und pharmazeutische zusammensetzung, die diese enthält | |
| FI3509595T3 (fi) | Hydroksipyridonaattiaktinidi-/lantanididekorporaatioaineiden formulaatioita | |
| HRP20110715T1 (hr) | Proizvodnja suspenzije vijabilnih, uskladištivih jaja helminta | |
| CN109646447A (zh) | 重楼皂苷在抗糠秕马拉色菌和白假丝酵母菌制品中的应用 | |
| JP2005041851A5 (hr) | ||
| TW200716142A (en) | Use of azithromycin for the manufacture of a medicament for treating ocular infections | |
| RU2016103912A (ru) | Новый способ применения железа и новые композиции, приспособленные для указанной цели | |
| Santana et al. | Combined effect of creatine monohydrate or creatine hydrochloride and caffeine supplementation in runners’ performance and body composition | |
| JP6159241B2 (ja) | 筋萎縮抑制剤 | |
| Savolainen et al. | Brain and blood lead in acute intoxication | |
| RU2007125078A (ru) | Состав ванны для ликвидации прихвата трубных колонн | |
| Kreider et al. | 15 Nutraceutical Application | |
| Delarosa et al. | Attenuation of short-term increased oxidative stress during martial arts competitions, and benefits of micronutrients for martial art athletes | |
| Kreider et al. | Nutraceutical Application of Creatine | |
| Di Carlo et al. | LEPTIN AND MENOPAUSE |